NR 565 Advanced Pharmacology Week 1 Quiz Chamberlain University
NR 565 Advanced Pharmacology Week 1 Quiz
Actual Exam (Latest Update)
Questions and Correct Verified Answers (100% Correct Verified Answers)
Chamberlain University
50 Questions | Multiple Choice
Section 1: Pharmacokinetics and Pharmacodynamics (Drug Absorption,
Distribution, Metabolism, Excretion, Receptor Theory, and Dose-Response)
Q1: A 55-year-old patient is prescribed an oral medication for hypertension. The nurse practitioner explains that
the drug undergoes extensive first-pass metabolism in the liver. Which of the following best describes the clinical
implication of the first-pass effect?
A. The drug will have a delayed onset of action due to slow gastric emptying
B. A significant portion of the orally administered drug is metabolized before reaching systemic
circulation, reducing bioavailability [CORRECT]
C. The drug will be rapidly excreted by the kidneys before reaching therapeutic levels
D. The drug will bind extensively to plasma proteins, limiting its free concentration
Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of orally administered drugs by the liver before they enter systemic
circulation. This process significantly reduces bioavailability compared to parenteral administration. Option A describes gastric
emptying effects on absorption rate, not first-pass metabolism. Option C describes renal excretion, which is unrelated to hepatic
first-pass metabolism. Option D describes plasma protein binding, a distribution phenomenon, not a metabolic process. IV drugs bypass
the first-pass effect entirely, achieving 100% bioavailability.
Q2: A nurse practitioner is comparing two formulations of the same drug: one oral tablet and one intravenous
injection. The IV formulation is described as having 100% bioavailability. Which statement best explains why
the oral formulation has lower bioavailability?
A. Oral drugs have smaller surface area for absorption compared to IV administration
B. Oral drugs undergo first-pass metabolism in the liver and may have incomplete absorption from the
GI tract [CORRECT]
C. IV drugs are distributed more rapidly to target tissues, increasing their effective concentration
D. Oral drugs are subject to renal tubular reabsorption, which reduces their systemic levels
Correct Answer: B
Rationale: Oral bioavailability is reduced by both incomplete absorption across the GI mucosa and first-pass hepatic metabolism
before the drug reaches systemic circulation. IV administration delivers the drug directly into the bloodstream, bypassing both
absorption barriers and hepatic first-pass metabolism, resulting in 100% bioavailability. Option A is incorrect because the GI tract has
a very large surface area due to villi and microvilli, which enhances absorption. Option C describes distribution kinetics, not
bioavailability. Option D incorrectly describes a renal mechanism that would increase, not decrease, drug levels.
Page 1
,NR 565 Advanced Pharmacology Week 1 Quiz Chamberlain University
Q3: A patient with a severe infection receives an antibiotic intravenously. The nurse practitioner notes that the
drug has a very high volume of distribution (Vd). Which of the following best interprets this finding?
A. The drug is primarily confined to the bloodstream and has limited tissue penetration
B. The drug is extensively distributed into tissues and body compartments beyond the plasma
[CORRECT]
C. The drug has a high therapeutic index and is safe at elevated doses
D. The drug is rapidly metabolized by the liver, requiring frequent dosing
Correct Answer: B
Rationale: Volume of distribution (Vd) is a hypothetical pharmacokinetic parameter that reflects the relationship between the amount
of drug in the body and the measured plasma concentration. A high Vd indicates that the drug is extensively distributed beyond the
plasma into tissues and body compartments, suggesting high tissue affinity. Option A describes a low Vd, the opposite. Option C
confuses Vd with therapeutic index. Option D confuses Vd with drug metabolism and clearance, which are separate pharmacokinetic
processes.
Q4: Which cytochrome P450 (CYP450) enzyme characteristic is most accurate regarding its role in phase I drug
metabolism?
A. CYP450 enzymes are located exclusively in the cytoplasm of hepatocytes and function independently of cell
membranes
B. CYP450 enzymes are membrane-bound proteins containing heme pigment responsible for oxidation,
reduction, and hydrolysis of xenobiotics [CORRECT]
C. CYP450 enzymes function only in phase II metabolism through conjugation reactions
D. CYP450 enzymes are primarily found in renal tubular cells and are responsible for drug excretion
Correct Answer: B
Rationale: CYP450 enzymes are membrane-bound hemoproteins located in the endoplasmic reticulum of hepatocytes and other tissues.
They contain a heme pigment essential for catalytic activity and are responsible for phase I oxidative reactions including oxidation,
reduction, and hydrolysis of xenobiotics. Option A is incorrect because CYP450 enzymes are bound to cell membranes, not free in the
cytoplasm. Option C is incorrect because phase II involves conjugation by transferase enzymes, not CYP450. Option D is incorrect
because CYP450 enzymes are primarily hepatic and metabolize rather than excrete drugs.
Q5: A nurse practitioner prescribes a medication that is a CYP450 enzyme inhibitor to a patient who is already
taking a drug metabolized by the same CYP450 pathway. What is the expected clinical outcome?
A. The metabolism of the first drug will increase, leading to decreased drug levels and potential therapeutic
failure
B. The metabolism of the first drug will decrease, leading to increased drug levels and potential toxicity
[CORRECT]
C. The excretion of the first drug will be enhanced, reducing its half-life
D. The distribution of the first drug will be altered, increasing its volume of distribution
Correct Answer: B
Rationale: CYP450 inhibitors reduce the metabolic activity of specific cytochrome P450 enzymes. When a patient takes a CYP450
inhibitor along with a drug metabolized by the same enzyme pathway, the metabolism of the co-administered drug is decreased. This
leads to increased plasma concentrations and potential toxicity. Option A describes the effect of a CYP450 inducer, not an inhibitor.
Option C incorrectly involves excretion, a separate ADME process. Option D incorrectly involves distribution, not directly affected by
CYP450 activity.
Page 2
, NR 565 Advanced Pharmacology Week 1 Quiz Chamberlain University
Q6: A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state concentration
with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 to 30 hours [CORRECT]
D. 48 to 60 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4 to 5 half-lives with repeated dosing. For a drug with a 6-hour
half-life, 4 half-lives equal 24 hours and 5 half-lives equal 30 hours, so steady-state is expected between 24 and 30 hours. Option A
represents only one half-life (50% of steady-state). Option B represents two half-lives (75% of steady-state). Option D would represent
8-10 half-lives, far beyond the time needed.
Q7: A nurse practitioner is managing a patient on digoxin therapy for heart failure. Which characteristic of
digoxin makes therapeutic drug monitoring essential?
A. Digoxin has a very large volume of distribution, making it difficult to measure plasma levels accurately
B. Digoxin has a narrow therapeutic index, meaning minor dose changes can cause serious adverse
effects or therapeutic failure [CORRECT]
C. Digoxin is primarily metabolized by CYP450 enzymes that are highly variable among patients
D. Digoxin is rapidly excreted by the kidneys, requiring hourly monitoring of serum levels
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is very small.
Minor changes in dose, renal function, or drug interactions can push serum levels into the toxic range causing serious adverse effects
such as cardiac arrhythmias, or below the therapeutic range resulting in treatment failure. Other narrow therapeutic index drugs
include lithium and warfarin. Option A describes Vd, not the primary reason for monitoring. Option C is incorrect because digoxin is
primarily eliminated renally. Option D is incorrect because digoxin has a long half-life (36 hours).
Q8: A patient with chronic obstructive pulmonary disease (COPD) uses an inhaled bronchodilator that acts on
beta-2 adrenergic receptors. Which of the four major receptor families does the beta-2 adrenergic receptor
belong to?
A. Ligand-gated ion channels
B. G protein-coupled receptors (GPCRs) [CORRECT]
C. Enzyme-linked receptors
D. Intracellular receptors
Correct Answer: B
Rationale: Beta-2 adrenergic receptors are members of the G protein-coupled receptor (GPCR) family, the largest family of
membrane receptors. GPCRs have three major subunits (alpha, beta, gamma) that generate intracellular second messengers and trigger
changes in cell function. Option A describes receptors like the nicotinic acetylcholine receptor. Option C describes receptors like the
insulin receptor with intrinsic tyrosine kinase activity. Option D describes receptors for lipid-soluble drugs such as corticosteroids and
thyroid hormones.
Q9: A nurse practitioner is teaching a student about G protein-coupled receptors (GPCRs). Which statement
accurately describes the mechanism of GPCRs?
A. GPCRs directly open ion channels in the cell membrane to allow rapid ion flow
Page 3
NR 565 Advanced Pharmacology Week 1 Quiz
Actual Exam (Latest Update)
Questions and Correct Verified Answers (100% Correct Verified Answers)
Chamberlain University
50 Questions | Multiple Choice
Section 1: Pharmacokinetics and Pharmacodynamics (Drug Absorption,
Distribution, Metabolism, Excretion, Receptor Theory, and Dose-Response)
Q1: A 55-year-old patient is prescribed an oral medication for hypertension. The nurse practitioner explains that
the drug undergoes extensive first-pass metabolism in the liver. Which of the following best describes the clinical
implication of the first-pass effect?
A. The drug will have a delayed onset of action due to slow gastric emptying
B. A significant portion of the orally administered drug is metabolized before reaching systemic
circulation, reducing bioavailability [CORRECT]
C. The drug will be rapidly excreted by the kidneys before reaching therapeutic levels
D. The drug will bind extensively to plasma proteins, limiting its free concentration
Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of orally administered drugs by the liver before they enter systemic
circulation. This process significantly reduces bioavailability compared to parenteral administration. Option A describes gastric
emptying effects on absorption rate, not first-pass metabolism. Option C describes renal excretion, which is unrelated to hepatic
first-pass metabolism. Option D describes plasma protein binding, a distribution phenomenon, not a metabolic process. IV drugs bypass
the first-pass effect entirely, achieving 100% bioavailability.
Q2: A nurse practitioner is comparing two formulations of the same drug: one oral tablet and one intravenous
injection. The IV formulation is described as having 100% bioavailability. Which statement best explains why
the oral formulation has lower bioavailability?
A. Oral drugs have smaller surface area for absorption compared to IV administration
B. Oral drugs undergo first-pass metabolism in the liver and may have incomplete absorption from the
GI tract [CORRECT]
C. IV drugs are distributed more rapidly to target tissues, increasing their effective concentration
D. Oral drugs are subject to renal tubular reabsorption, which reduces their systemic levels
Correct Answer: B
Rationale: Oral bioavailability is reduced by both incomplete absorption across the GI mucosa and first-pass hepatic metabolism
before the drug reaches systemic circulation. IV administration delivers the drug directly into the bloodstream, bypassing both
absorption barriers and hepatic first-pass metabolism, resulting in 100% bioavailability. Option A is incorrect because the GI tract has
a very large surface area due to villi and microvilli, which enhances absorption. Option C describes distribution kinetics, not
bioavailability. Option D incorrectly describes a renal mechanism that would increase, not decrease, drug levels.
Page 1
,NR 565 Advanced Pharmacology Week 1 Quiz Chamberlain University
Q3: A patient with a severe infection receives an antibiotic intravenously. The nurse practitioner notes that the
drug has a very high volume of distribution (Vd). Which of the following best interprets this finding?
A. The drug is primarily confined to the bloodstream and has limited tissue penetration
B. The drug is extensively distributed into tissues and body compartments beyond the plasma
[CORRECT]
C. The drug has a high therapeutic index and is safe at elevated doses
D. The drug is rapidly metabolized by the liver, requiring frequent dosing
Correct Answer: B
Rationale: Volume of distribution (Vd) is a hypothetical pharmacokinetic parameter that reflects the relationship between the amount
of drug in the body and the measured plasma concentration. A high Vd indicates that the drug is extensively distributed beyond the
plasma into tissues and body compartments, suggesting high tissue affinity. Option A describes a low Vd, the opposite. Option C
confuses Vd with therapeutic index. Option D confuses Vd with drug metabolism and clearance, which are separate pharmacokinetic
processes.
Q4: Which cytochrome P450 (CYP450) enzyme characteristic is most accurate regarding its role in phase I drug
metabolism?
A. CYP450 enzymes are located exclusively in the cytoplasm of hepatocytes and function independently of cell
membranes
B. CYP450 enzymes are membrane-bound proteins containing heme pigment responsible for oxidation,
reduction, and hydrolysis of xenobiotics [CORRECT]
C. CYP450 enzymes function only in phase II metabolism through conjugation reactions
D. CYP450 enzymes are primarily found in renal tubular cells and are responsible for drug excretion
Correct Answer: B
Rationale: CYP450 enzymes are membrane-bound hemoproteins located in the endoplasmic reticulum of hepatocytes and other tissues.
They contain a heme pigment essential for catalytic activity and are responsible for phase I oxidative reactions including oxidation,
reduction, and hydrolysis of xenobiotics. Option A is incorrect because CYP450 enzymes are bound to cell membranes, not free in the
cytoplasm. Option C is incorrect because phase II involves conjugation by transferase enzymes, not CYP450. Option D is incorrect
because CYP450 enzymes are primarily hepatic and metabolize rather than excrete drugs.
Q5: A nurse practitioner prescribes a medication that is a CYP450 enzyme inhibitor to a patient who is already
taking a drug metabolized by the same CYP450 pathway. What is the expected clinical outcome?
A. The metabolism of the first drug will increase, leading to decreased drug levels and potential therapeutic
failure
B. The metabolism of the first drug will decrease, leading to increased drug levels and potential toxicity
[CORRECT]
C. The excretion of the first drug will be enhanced, reducing its half-life
D. The distribution of the first drug will be altered, increasing its volume of distribution
Correct Answer: B
Rationale: CYP450 inhibitors reduce the metabolic activity of specific cytochrome P450 enzymes. When a patient takes a CYP450
inhibitor along with a drug metabolized by the same enzyme pathway, the metabolism of the co-administered drug is decreased. This
leads to increased plasma concentrations and potential toxicity. Option A describes the effect of a CYP450 inducer, not an inhibitor.
Option C incorrectly involves excretion, a separate ADME process. Option D incorrectly involves distribution, not directly affected by
CYP450 activity.
Page 2
, NR 565 Advanced Pharmacology Week 1 Quiz Chamberlain University
Q6: A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state concentration
with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 to 30 hours [CORRECT]
D. 48 to 60 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4 to 5 half-lives with repeated dosing. For a drug with a 6-hour
half-life, 4 half-lives equal 24 hours and 5 half-lives equal 30 hours, so steady-state is expected between 24 and 30 hours. Option A
represents only one half-life (50% of steady-state). Option B represents two half-lives (75% of steady-state). Option D would represent
8-10 half-lives, far beyond the time needed.
Q7: A nurse practitioner is managing a patient on digoxin therapy for heart failure. Which characteristic of
digoxin makes therapeutic drug monitoring essential?
A. Digoxin has a very large volume of distribution, making it difficult to measure plasma levels accurately
B. Digoxin has a narrow therapeutic index, meaning minor dose changes can cause serious adverse
effects or therapeutic failure [CORRECT]
C. Digoxin is primarily metabolized by CYP450 enzymes that are highly variable among patients
D. Digoxin is rapidly excreted by the kidneys, requiring hourly monitoring of serum levels
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is very small.
Minor changes in dose, renal function, or drug interactions can push serum levels into the toxic range causing serious adverse effects
such as cardiac arrhythmias, or below the therapeutic range resulting in treatment failure. Other narrow therapeutic index drugs
include lithium and warfarin. Option A describes Vd, not the primary reason for monitoring. Option C is incorrect because digoxin is
primarily eliminated renally. Option D is incorrect because digoxin has a long half-life (36 hours).
Q8: A patient with chronic obstructive pulmonary disease (COPD) uses an inhaled bronchodilator that acts on
beta-2 adrenergic receptors. Which of the four major receptor families does the beta-2 adrenergic receptor
belong to?
A. Ligand-gated ion channels
B. G protein-coupled receptors (GPCRs) [CORRECT]
C. Enzyme-linked receptors
D. Intracellular receptors
Correct Answer: B
Rationale: Beta-2 adrenergic receptors are members of the G protein-coupled receptor (GPCR) family, the largest family of
membrane receptors. GPCRs have three major subunits (alpha, beta, gamma) that generate intracellular second messengers and trigger
changes in cell function. Option A describes receptors like the nicotinic acetylcholine receptor. Option C describes receptors like the
insulin receptor with intrinsic tyrosine kinase activity. Option D describes receptors for lipid-soluble drugs such as corticosteroids and
thyroid hormones.
Q9: A nurse practitioner is teaching a student about G protein-coupled receptors (GPCRs). Which statement
accurately describes the mechanism of GPCRs?
A. GPCRs directly open ion channels in the cell membrane to allow rapid ion flow
Page 3
